Search results
Added:
1 year ago
Added:
5 months ago
Source:
Radcliffe Cardiology
The US Food and Drug Administration (FDA) has approved the non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) finerenone (Kerendia, Bayer). The new indication is for adult patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≥40% to reduce the risk of cardiovascular death, hospitalisation for heart failure, and urgent heart failure visits.¹ The…
View more
Added:
2 years ago
ESC 2023 — Dr Jozine Ter Maaten (University Medical Centre Groningen, NL) joins us to outline the findings from the PUSH-AHF Study (NCT04606927).
PUSH-AHF (University Medical Center Groningen) aimed to assess the effect of natriuresis-guided therapy in patients with acute heart failure to improve diagnostic response, decongestion and clinical outcomes. 310 patients with a primary diagnosis of…
View more
Added:
9 months ago
Added:
1 month ago
Added:
5 months ago
Source:
Radcliffe Cardiology
A new nationwide cohort study from France suggests that a simple risk stratification tool based on administrative data could help tailor cardiologist follow-up for patients with heart failure (HF), potentially improving survival and optimising resource use. The study found that 40% of patients with HF do not have an annual cardiology consultation, regardless of their disease severity.¹The French…
View more
Added:
6 months ago
Added:
7 months ago
‘Residual Congestion’ in HF
Added:
10 months ago
Article
Added:
7 months ago